Larimar Therapeutics (LRMR) Non-Current Assets (2013 - 2025)
Larimar Therapeutics (LRMR) posted Non-Current Assets of $3.8 million for Q4 2025, down 7.44% on a QoQ basis from $4.1 million in Q3 2025, and down 22.37% year-over-year from $4.9 million in Q4 2024.
Larimar Therapeutics (LRMR) Non-Current Assets (2013 - 2025) Analysis & Trends
Larimar Therapeutics' Non-Current Assets history runs 13 years deep, the most recent figure standing at $3.8 million for Q4 2025.
- Quarterly Non-Current Assets fell 22.37% year-over-year to $3.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $17.1 million (down 49.75% YoY) and the FY2025 annual result came in at $3.8 million, down 22.37% from the prior year.
- Non-Current Assets was $3.8 million for Q4 2025 at Larimar Therapeutics, down from $4.1 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $17.3 million in Q1 2024 and bottomed at $3.8 million in Q4 2025.
- A 5-year average of $6.2 million and a median of $5.8 million in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets soared 216.96% — and 2025, when it plunged 72.81%.
- Larimar Therapeutics' Non-Current Assets stood at $6.5 million in 2021, then decreased by 12.33% to $5.7 million in 2022, then gained by 1.66% to $5.8 million in 2023, then decreased by 14.57% to $4.9 million in 2024, then fell by 22.37% to $3.8 million in 2025.
- Business Quant data shows LRMR's Non-Current Assets at $3.8 million in Q4 2025, $4.1 million in Q3 2025, and $4.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 5.83 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 30.30 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1.95 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 285.82 Mn |
| 10 | Larimar Therapeutics | 37.00 Mn | -99.85 Mn | - | 3.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.82 Mn |
| Sep 30, 2025 | 4.13 Mn |
| Jun 30, 2025 | 4.43 Mn |
| Mar 31, 2025 | 4.69 Mn |
| Dec 31, 2024 | 4.92 Mn |
| Sep 30, 2024 | 5.77 Mn |
| Jun 30, 2024 | 6.03 Mn |
| Mar 31, 2024 | 17.25 Mn |
| Dec 31, 2023 | 5.76 Mn |
| Sep 30, 2023 | 5.47 Mn |
| Jun 30, 2023 | 5.24 Mn |
| Mar 31, 2023 | 5.44 Mn |
| Dec 31, 2022 | 5.67 Mn |
| Sep 30, 2022 | 5.89 Mn |
| Jun 30, 2022 | 6.11 Mn |
| Mar 31, 2022 | 6.34 Mn |
| Dec 31, 2021 | 6.46 Mn |
| Sep 30, 2021 | 6.69 Mn |
| Jun 30, 2021 | 6.90 Mn |
| Mar 31, 2021 | 6.89 Mn |